Dibenzazepinyl ureas as dual NMR and CD probes of helical screw-sense preference in conformationally equilibrating dynamic foldamers

Vincent Diemer, Julien Maury, Bryden A. F. Le Bailly, Simon J. Webb and Jonathan Clayden

School of Chemistry, University of Bristol, Cantock's Close, Bristol BS8 1TS, UK

Supporting Information

Table of Contents

General Experimental and Materials	
Instrumentation	
Synthetic Procedures and characterisations	S4
NMR spectra of synthesized peptides	S31
Helical excess determination	S56
NMR and CD analysis of peptides 2a-j and 2x	
References	S62

General Experimental and Materials

All reactions were carried out in oven-dried glassware under an atmosphere of nitrogen using standard anhydrous techniques. All reagents were obtained from commercially available sources and used without further purification, or where indicated prepared internally. Air- and moisture- sensitive liquids and solutions were transferred *via* syringe or stainless steel cannula. Reactions performed at 0 °C were done so using an ice bath. Anhydrous dichloromethane was obtained by distillation from calcium hydride. Other anhydrous reaction solvents were obtained from standard anhydrous solvent engineering system. Triethylamine was stored over potassium hydroxide. All products were dried on a rotary evaporator followed by connection to a high vacuum system to remove any residual solvent. Flash chromatography was performed on silica gel (Merck 60H, 40-60 nm, 230 – 300 mesh). Analytical thin layer chromatography was performed on aluminium backed silica (60 F254) plates.

Instrumentation

All ¹H and ¹³C nuclear magnetic resonance spectra were obtained using Bruker AVANCE 300, 400 or 500 MHz spectrometers. Chemical shifts are quoted in parts per million (ppm), and coupling constants (*J*) are quoted in Hz to the nearest 0.5 Hz. ¹H-NMR spectra were referenced to the residual deuterated solvent peak (CDCl₃ 7.26; CD₃OD 3.31) and ¹³C-NMR were referenced to the carbon resonance of the solvent (CDCl₃ 77.16; CD₃OD 49.00). Multiplicities are denoted as s (singlet), d (doublet), t (triplet), q (quartet), quin (quintuplet), spt (septet) and m (multiplet) or denoted as br (broad), or some combination of these, where appropriate. Where ¹H-NMR spectra were run in CD₃OD, D₂O or CD₃CD₂OD exchangeable protons (NH, OH) are reported only where observed.

Infra-red spectra were recorded on an ATi Perkin Elmer Spectrum RX1 FT-IR spectrometer. Only absorption maxima (λ_{max}) of interest are reported and quoted in wavenumbers (cm⁻¹). Low and high resolution mass spectra were recorded by staff at the University of Manchester. Electrospray (ES) spectra were recorded on a Waters Platform II and high resolution mass spectra (HRMS) were recorded on a Thermo Finnigan MAT95XP and are accurate to \pm 0.001 Da. Melting points were determined on a GallenKamp apparatus and are uncorrected. Optical rotation measurements were taken on an AA-100 polarimeter at 20 °C with the solvent and concentration stated. Circular Dichroism (CD) measurements were performed at 20 °C on a JASCO J-815 spectropolarimeter, using a 1 mm cell with the solvent and concentration stated, where applicable.

Synthetic procedures and characterisation

Methods for the synthesis of NH_2 -(L)-PheNH*t*Bu,^[1] NH_2 -(L)-*t*LeuNH*t*Bu,^[1] NH_2 -(L)-AlaNH*t*Bu,^[1] 1 (as a free amine),^[2] N_3Aib_4OH (3),^[3] NH_2Aib_4OtBu (5x)^[3] and oligoureas $7a^{[4]}$ and $7b^{[4]}$ were reported previously.

General procedure A: Hydrogenolysis of $N_3Aib_n-X_{aa}-Y$ (n = 4, 8, 12; Xaa = Ala, Phe, *t*Leu, Val; Y =NH*t*Bu, O*t*Bu)

To a solution of $N_3Aib_n-X_{aa}-Y$ (1 eq) in MeOH was added Pd/C (10%) and the resultant mixture was stirred under a H₂ atmosphere until completion of the reaction (TLC monitoring). After this time, the reaction mixture was filtered through a pad of Celite[©] under vacuum and the filtrate collected. The residue obtained after evaporation of the solvent under reduced pressure was dissolved in CH₂Cl₂ and the organic layer was washed with 0.5 M K₂CO₃ (2 ×) and dried over MgSO₄. After evaporation of the solvent under reduced amine was used in the next step without further purification.

General procedure B: azlactone synthesis

To a solution of **3** (200 mg, 0.52 mmol) in CH_2Cl_2 (5 mL) was added EDC•HCl (197 mg, 1.03 mmol). The reaction mixture was stirred at RT for 16 h and the solvent was evaporated under reduced pressure. The residue was dissolved in EtOAc (50 mL) and the organic layer was successively washed with 5% KHSO₄ (2 × 25 mL), sat. NaHCO₃ (2 × 25 mL) and brine (25 mL) and was dried over MgSO₄. Evaporation of the solvent under reduced pressure provided the expected azlactone (153 mg) which was used in the next step without further purification.

General procedure C: synthesis of AzeCl

To a solution of triphosgene (158 mg, 0.53 mmol) in CH₂Cl₂ (1.2 mL) cooled at -78 °C was added dropwise a solution of 1 (226 mg, 1.16 mmol) in CH₂Cl₂ (1 mL). The reaction mixture was stirred at -78 °C for 30 min and was then warmed up to RT. After 3 h stirring, the reaction mixture was quenched with 1 M HCl (15 mL) and the resulting aqueous layer was extracted with CH₂Cl₂ (3 × 15 mL). The combined organic layers were washed with sat. NaHCO₃ (10 mL) and were dried over MgSO₄. Evaporation of the solvent under reduced pressure provided **AzeCl** which was used in the next step without further purification. ¹H **NMR** (500 MHz, CDCl₃) δ 7.48-7.58 (m, 4 H), 7.38-7.48 (m, 4 H), 4.52 (s, 2 H), 4.42 (s, 2 H) ppm.

AzeAib₄-(L)-AlaNH*t*Bu (2a)



To a suspension of DSC (76 mg, 0.30 mmol) in CH₂Cl₂ (1.5 mL) was added dropwise at 0 °C a solution of **5a** (100 mg, 0.21 mmol, obtained by hydrogenolysis of **4a** following general procedure A) in CH₂Cl₂ (3.0 mL). The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed with 5% KHSO₄ (2 × 25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, the residue was dissolved in CH₃CN (2.5 mL) and this solution was added dropwise to a mixture of **1**·HCl (48 mg, 0.21 mmol) and DIPEA (0.82 mmol, 143 µL) in CH₃CN (1.5 mL) cooled at 0°C. The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (100 mL).

75:25) provided the titled compound (86 mg, 59%) as a colourless solid. $\mathbf{mp} = 216-217 \,^{\circ}\text{C}$. **IR** (solid) v_{max} 3302, 2984, 1644, 1529, 1452, 1381, 1360, 1290, 1226, 1165 cm⁻¹. $[\alpha]_{\mathbf{p}}^{20} =$ +63.5 (c = 0.51, CH₂Cl₂). ¹**H NMR** (400 MHz, CDCl₃) δ 1.30 (s, 3 H, C<u>H</u>₃), 1.38 (s, 9 H, *t*Bu), 1.43 (s, 3 H, C<u>H</u>₃), 1.44 (d, 3 H, *J* = 7.1 Hz, CHC<u>H</u>₃), 1.47 (s, 3 H, C<u>H</u>₃), 1.49 (s, 3 H, C<u>H</u>₃), 1.52 (s, 3 H, C<u>H</u>₃), 1.54 (s, 3 H, C<u>H</u>₃), 1.55 (s, 3 H, C<u>H</u>₃), 1.58 (s, 3 H, C<u>H</u>₃), 4.16 (d, 2 H, *J* = 12.7 Hz, A of AB, ArC<u>H</u>₂), 4.30-4.38 (m, 1 H, CH₃C<u>H</u>), 4.37 (d, 2 H, *J* = 12.7 Hz, B of AB, ArC<u>H</u>₂), 5.20 (s, 1H, N<u>H</u>), 6.48 (s, 1 H, N<u>H</u>), 6.95 (s, 1 H, N<u>H</u>), 7.37-7.42 (m, 4 H, 4 × H_{ar}), 7.47-7.57 (m, 5 H, 4 × <u>H</u>_{ar} + N<u>H</u>), 7.66 (d, 1 H, *J* = 7.9 Hz, N<u>H</u>), 8.29 (s, 1 H, N<u>H</u>) ppm. ¹³C **NMR** (100 MHz, CDCl₃) δ 17.4 (CH₃), 23.2 (CH₃), 23.50 (CH₃), 23.53 (CH₃), 24.1 (CH₃), 27.2 (CH₃), 27.42 (CH₃), 27.44 (CH₃), 27.7 (CH₃) 28.8 (3 × CH₃), 48.1 (2 × CH₂), 50.1 (CH), 51.3 (C), 56.6 (C), 57.05 (C), 57.09 (C), 57.6 (C), 128.6 (2 × CH), 128.7 (2 × CH), 129.2 (2 × CH), 129.5 (2 × CH), 133.8 (2 × C), 140.5 (2 × C), 156.4 (CO), 173.0 (CO), 174.92 (CO), 174.95 (CO), 175.1 (CO), 175.5 (CO) ppm. **MS** (ES⁺, MeOH): 706.5 ([M+H]⁺, 20%), 728.6 ([M+Na]⁺, 50%). **HRMS** (ES⁺, MeOH) calcd for C₃₈H₅₆N₇O₆ = 706.4287; found 706.4279.

AzeAib₄-(L)-PheNH*t*Bu (2b)



To a suspension of DSC (28 mg, 0.109 mmol) in CH_2Cl_2 (0.5 mL) was added dropwise at 0 °C a solution of **5b** (39 mg, 0.069 mmol, obtained by hydrogenolysis of **4b** following general procedure A) in CH_2Cl_2 (1.0 mL). The reaction mixture was stirred overnight at RT and was diluted with CH_2Cl_2 (100 mL). The organic layer was washed with 5% KHSO₄ (2 × 25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, the

residue was dissolved in CH₃CN (0.5 mL) and this solution was added dropwise to a mixture of 1·HCl (25 mg, 0.108 mmol) and DIPEA (75 µL, 0.432 mmol) in CH₃CN (0.25 mL) cooled at 0°C. The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (50 mL). The organic layer was washed successively with 5% KHSO₄ (2×20 mL), NaHCO₃ ($2 \times$ 20 mL) and brine (10 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 3:7 \rightarrow 4:6) provided the titled compound (20 mg, 37%) as a colourless solid. **mp** = 219-221 °C. IR (solid) v_{max} 3294, 2981, 2930, 2868, 1651, 1632, 1529, 1148, 1383, 1360, 1227, 1169 cm⁻¹. $[\alpha]_{D}^{20} = +46.4^{\circ}$ (c = 0.50, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 1.18 (s, 3 H, CH₃), 1.30 (s, 3 H, CH₃), 1.41 (s, 9 H, tBu), 1.44 (s, 3 H, CH₃), 1.45 (s, 3 H, CH₃), 1.47 (s, 3 H, CH_3), 1.51 (s, 3 H, CH_3), 1.54 (s, 3 H, CH_3), 1.55 (s, 3 H, CH_3), 2.91 (dd, 1 H, J = 14.3 and 12.3 Hz, PheCH₂CH), 3.63 (dd, 1 H, J = 14.3 and 2.7 Hz, PheCH₂CH), 4.14 (d, 2 H, J = 12.6 Hz, A of AB, ArCH₂N), 4.37 (d, 2 H, J = 12.6 Hz, B of AB, ArCH₂N), 4.54-4.60 (m, 1 H, PheCH₂CH), 5.18 (s, 1H, NH), 6.44 (s, 1 H, NH), 7.07-7.11 (m, 2 H, H_{ar} + NH), 7.16 (t, 2 H, $J = 7.3 \text{ Hz}, 2 \times \text{H}_{ar}$, 7.29 (d, 2 H, $J = 7.3 \text{ Hz}, 2 \times \text{H}_{ar}$), 7.36-7.42 (m, 4 H, 4 × H_{ar}), 7.46-7.53 (m, 4 H, $2 \times NH + 2 \times Har$), 7.55 (d, 2 H, J = 7.2 Hz, $2 \times Har$), 8.19 (s, 1 H, NH) ppm. ¹³C NMR (125 MHz, CDCl₃) δ 23.3 (CH₃), 23.4 (CH₃), 23.6 (CH₃), 24.0 (CH₃), 27.0 (CH₃), 27.1 (CH₃), 27.26 (CH₃), 27.30 (CH₃), 28.7 (3 × CH₃), 37.0 (CH₂), 48.0 (2 × CH₂), 51.2 (C), 55.4 (CH), 56.5 (C), 56.8 (C), 56.9 (C), 57.4 (C), 125.9 (CH), 128.0 (2 × CH), 128.48 (2 × CH), 128.52 (2 × CH), 129.1 (2 × CH), 129.2 (2 × CH), 129.3 (2 × CH), 133.5 (C), 139.3 (2 × C), 140.3 (2 × C), 156.1 (CO), 171.2 (CO), 174.4 (CO), 174.6 (CO), 174.97 (CO), 175.04 (CO) ppm. **MS** (ES⁺, MeOH): 783 ([M+H]⁺, 28%), 805 ([M+Na]⁺, 100%); **MS** (ES⁻, MeOH): 781 $([M-H]^{-}, 79\%)$. **HRMS** (ES⁺, MeOH) calcd for C₄₄H₆₀N₇O₆ = 782.4600; found 782.4602.

AzeAib₄-(L)-*t*LeuNH*t*Bu (2c)



To a suspension of DSC (27 mg, 0.105 mmol) in CH₂Cl₂ (0.75 mL) was added dropwise at 0 °C a solution of 5c (39 mg, 0.074 mmol, obtained by hydrogenolysis of 4c following general procedure A) in CH₂Cl₂ (1.5 mL). The reaction mixture was stirred overnight at RT and was diluted with CH_2Cl_2 (100 mL). The organic layer was washed with 5% KHSO₄ (2 × 25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, the residue was dissolved in CH₃CN (1.5 mL) and this solution was added dropwise to a mixture of 1·HCl (17 mg, 0.073 mmol) and DIPEA (51 µL, 0.296 mmol) in CH₃CN (0.75 mL) cooled at 0°C. The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed successively with 5% KHSO₄ (2×40 mL), NaHCO₃ ($2 \times$ 40 mL) and brine (20 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 5:5 \rightarrow 4:6) provided the titled compound (38 mg, 69%) as a colourless solid. mp = 205-207 °C. IR (solid) v_{max} 3283, 2981, 2933, 2872, 1652, 1644, 1626, 1531, 1451, 1383, 1360, 1287, 1260, 1166 cm⁻¹. $[\alpha]_D^{20} = +42.4$ (c = 0.50, MeOH/CH₂Cl₂ 1:9). ¹H NMR (400 MHz, CDCl₃/CD₃OH 97:3) & 1.07 (s, 9 H, *t*Bu), 1.27 (s, 3 H, CH₃), 1.33 (s, 9 H, *t*Bu), 1.40 (s, 3 H, CH₃), 1.41 (s, 3 H, CH₃), 1.45 (s, 3 H, CH₃), 1.47 (s, 6 H, $2 \times CH_3$), 1.50 (s, 6 H, $2 \times CH_3$), 3.94 (d, 1H, *J* = 7.8 Hz, CH*t*Bu), 4.10 (d, 2 H, *J* = 12.6 Hz, A of AB, ArCH₂N), 4.35 (d, 2 H, J = 12.6 Hz, B of AB, ArCH₂N), 5.43 (s, 1H, NH), 6.65 (s, 1 H, NH), 6.78 (s, 1 H, NH), 7.26 (d, 1H, J = 7.8 Hz, NH), 7.31-7.41 (m, 4 H, 4 × Har), 7.44-7.50 (m, 2 H, 2 × Har), 7.52 (d, 2 H, J = 7.4 Hz, $2 \times H_{ar}$), 7.63 (s, 1 H, NH), 8.18 (s, 1 H, NH) ppm. ¹³C NMR (100 MHz, CDCl₃/CD₃OH 97:3) & 23.4 (CH₃), 23.47 (CH₃), 23.51 (CH₃), 24.0 (CH₃), 27.0 (CH₃), 27.1

(CH₃), 27.2 (CH₃), 27.3 (3 × CH₃), 27.6 (CH₃), 28.6 (3 × CH₃), 33.8 (C), 47.9 (2 × CH₂), 51.3 (C), 56.5 (C), 56.87 (C), 56.95 (C), 57.3 (C), 63.5 (CH), 128.5 (4 × CH), 129.1 (2 × CH), 129.4 (2 × CH), 133.8 (2 × C), 140.4 (2 × C), 156.4 (CO), 171.1 (CO), 174.6 (CO), 175.3 (2 × CO), 175.6 (CO) ppm. **MS** (ES⁺, DCM): 748.7 ([M+H]⁺, 30%), 770.7 ([M+Na]⁺, 20%). **HRMS** (ES⁺, MeOH) calcd for C₄₁H₆₂N₇O₆ = 748.4756; found 748.4756.

AzeAib₄-(L)-AlaOtBu (2d)



To a suspension of DSC (103 mg, 0.31 mmol) in CH₂Cl₂ (1.5 mL) was added dropwise at 0 °C a solution of **5d** (103 mg, 0.21 mmol, obtained by hydrogenolysis of **4d** following general procedure A) in CH₂Cl₂ (3 mL). The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (75 mL). The organic layer was washed with 5% KHSO₄ (2 × 25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, the residue was dissolved in CH₃CN (2.5 mL) and this solution was added dropwise to a mixture of **1**·HCl (49 mg, 0.21 mmol) and DIPEA (0.84 mmol, 146 µL) in CH₃CN (1.5 mL) cooled at 0°C. The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed successively with NaHCO₃ (2 × 25 mL), 5% KHSO₄ (2 × 25 mL) and brine (25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 1:1) provided the titled compound (113 mg, 76%) as a colourless solid. Spectroscopic data of **2d** (NMR, IR, MS) are identical to the spectroscopic data of **2e**. [α]_D²⁰ = -75.2 (c = 0.50, MeOH).

AzeAib₄-(D)-AlaOtBu (2e)



To a suspension of DSC (119 mg, 0.46 mmol) in CH₂Cl₂ (2.2 mL) was added dropwise at 0 °C a solution of 5e (157 mg, 0.32 mmol, obtained by hydrogenolysis of 4e following general procedure A) in CH₂Cl₂ (4.5 mL). The reaction mixture was stirred overnight at RT and was diluted with CH_2Cl_2 (75 mL). The organic layer was washed with 5% KHSO₄ (2 × 25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, the residue was dissolved in CH₃CN (3.75 mL) and this solution was added dropwise to a mixture of 1·HCl (75 mg, 0.32 mmol) and DIPEA (1.28 mmol, 222 µL) in CH₃CN (2.2 mL) cooled at 0°C. The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed successively with 5% KHSO₄ (2×25 mL), NaHCO₃ (2×25 mL) and brine (25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 1:1) provided the titled compound (188 mg, 82%) as a colourless solid. mp = 217-218 °C. $[\alpha]_{D}^{20} = +80.0$ (c = 0.51, MeOH). IR (solid) v_{max} 3305, 2981, 2935, 1656, 1629, 1528, 1454, 1382, 1361, 1228, 1151 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 1.33 (s, 3 H, C<u>H</u>₃), 1.42 (d, 3 H, J = 7.0 Hz, CH₃), 1.43 (s, 9 H, tBu), 1.45 (s, 3 H, CH₃), 1.47 (s, 3 H, CH₃), 1.51 (s, 3 H, CH₃), 1.53 (s, 3 H, CH₃), 1.54 (s, 3 H, CH₃), 1.55 (s, 3 H, CH₃), 1.56 (s, 3 H, CH₃), 4.18 (d, 2 H, J =12.6 Hz, A of AB, ArCH₂N), 4.32 (d, 2 H, J = 12.6 Hz, B of AB, ArCH₂N), 4.31-4.38 (m, 1 H, C<u>H</u>-CH₃), 4.99 (s, 1H, N<u>H</u>), 6.37 (s, 1 H, N<u>H</u>), 7.34-7.43 (m, 5 H, $4 \times H_{Ar} + NH$), 7.44-7.53 (m, 3 H, $2 \times \underline{H}_{Ar} + N\underline{H}$), 7.54-7.57 (m, 2 H, $2 \times \underline{H}_{Ar}$), 8.10 (s, 1 H, N<u>H</u>) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 17.1 (CH₃), 24.2-24.3 (m, 3 × CH₃), 24.8 (CH₃), 26.59 (CH₃), 26.65 (CH₃), 26.7 (CH₃), 27.2 (CH₃), 28.1 (3 × CH₃), 48.2 (2 × CH₂), 49.4 (CH), 56.6 (C), 57.0 (C), 57.1 (C), 57.5 (C), 80.6 (C), 128.6 (4 × CH), 129.1 (2 × CH), 129.5 (2 × CH), 133.9 (2 × C), 140.5 (2 × C), 156.4 (CO), 172.7 (CO), 174.4 (CO), 174.7 (CO), 174.8 (CO), 175.2 (CO) ppm. **MS** (ES⁺, MeOH): 707.5 ([M+H]⁺, 80%), 729.5 ([M+Na]⁺, 45%). **HRMS** (ES⁺, MeOH) calcd for $C_{38}H_{55}N_6O_7 = 707.4127$; found 707.4121.

AzeAib₄-(L)-ValOtBu (2f)



To a suspension of DSC (66 mg, 0.258 mmol) in CH₂Cl₂ (1.5 mL) was added dropwise at 0 °C a solution of 5f (91 mg, 0.177 mmol, obtained by hydrogenolysis of 4f following general procedure A) in CH₂Cl₂ (3 mL). The reaction mixture was stirred overnight at RT and was diluted with CH_2Cl_2 (100 mL). The organic layer was washed with 5% KHSO₄ (2 × 25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, the residue was dissolved in CH₃CN (3 mL) and this solution was added dropwise to a mixture of 1.HCl (41 mg, 0.177 mmol) and DIPEA (123 µL, 0.708 mmol) in CH₃CN (1.5 mL) cooled at 0°C. The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (50 mL). The organic layer was washed successively with 5% KHSO₄ (2×20 mL), NaHCO₃ (2×20 mL) and brine (10 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 1:1) provided the titled compound (112 mg, 86%) as a colourless solid. mp = 215-217 °C. $[\alpha]_{D}^{20} = -35.9$ (c = 0.58, CH₂Cl₂). **IR** (solid) v_{max} 3288, 2980, 2934, 2873, 1726, 1653, 1629, 1524, 1454, 1382, 1361, 1228, 1161 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 1.00 (d, 3 H, J = 6.9 Hz, $CH(CH_3)_2$), 1.02 (d, 3 H, J = 6.9 Hz, $CH(CH_3)_2$), 1.35 (s, 3 H, CH_3), 1.43-1.47 (m, 12 H, *t*Bu + CH₃), 1.48 (s, 3 H, CH₃), 1.51 (s, 3 H, CH₃), 1.52-1.58 (m, 12 H, 4 × CH₃), 2.16-2.28 (m, 1 H, C<u>H</u>(CH₃)₂), 4.19 (d, 2 H, *J* = 12.7 Hz, A of AB, C<u>H</u>₂Ar), 4.24 (br t, 1 H, *J* = 7.4 Hz,

C<u>H</u>CH(CH₃)₂), 4.30 (d, 2 H, J = 12.7 Hz, B of AB, C<u>H</u>₂Ar), 4.78 (s, 1H, N<u>H</u>), 6.32 (s, 1 H, N<u>H</u>), 7.30 (d, 1 H, J = 8.2 Hz, N<u>H</u>), 7.35-7.44 (m, 5 H, N<u>H</u> + 4 × <u>H</u>_{ar}), 7.48-7.59 (m, 4 H, 4 × <u>H</u>_{ar}), 7.98 (s, 1 H, N<u>H</u>) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 18.7 (CH₃), 19.3 (CH₃), 24.7 (3 × CH₃), 25.1 (CH₃), 26.3 (CH₃), 26.4 (CH₃), 26.5 (CH₃), 26.9 (CH₃), 28.2 (3 × CH₃), 30.4 (CH), 48.1 (2 × CH₂), 56.7 (C), 57.0 (C), 57.1 (C), 57.5 (C), 59.5 (CH), 80.6 (C), 128.6 (4 × CH), 129.2 (2 × CH), 129.5 (2 × CH), 133.8 (2 × C), 140.4 (2 × C), 156.2 (CO), 171.3 (CO), 174.06 (CO), 174.10 (CO), 174.5 (CO), 175.5 (CO) ppm. MS (ES⁺, MeOH): 735.6 ([M+H]⁺, 50%), 757.6 ([M+Na]⁺, 35%). HRMS (ES⁺, MeOH) calcd for C₄₀H₅₉N₆O₇ = 735.4440; found 735.4437.

AzeAib₄-(L)-PheOtBu (2g)



To a suspension of DSC (40 mg, 0.156 mmol) in CH₂Cl₂ (0.75 mL) was added dropwise at 0 °C a solution of **5g** (61 mg, 0.108 mmol, obtained by hydrogenolysis of **4g** following general procedure A) in CH₂Cl₂ (1.5 mL). The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed with 5% KHSO₄ (2 × 25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, the residue was dissolved in CH₃CN (1.5 mL) and this solution was added dropwise to a mixture of **1**·HCl (25 mg, 0.108 mmol) and DIPEA (75 μ L, 0.432 mmol) in CH₃CN (0.75 mL) cooled at 0°C. The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (50 mL). The organic layer was washed successively with 5% KHSO₄ (2 × 15 mL), NaHCO₃ (2 × 15 mL) and brine (15 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure in the reduced pressure, the reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (50 mL). The organic layer was washed successively with 5% KHSO₄ (2 × 15 mL), NaHCO₃ (2 × 15 mL) and brine (15 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂

4:6) provided the titled compound (61 mg, 72%) as a colourless solid. mp = 197-199 °C. $[\alpha]_{D}^{25} = -35.2$ (c = 1.00, MeOH). IR (solid) v_{max} 3304, 2981, 2932, 1651, 1629, 1527, 1454, 1382, 1361, 1228, 1153 cm⁻¹. ¹H NMR (500 MHz, CDCl₃) δ 1.32 (s, 9 H, *t*Bu), 1.34 (s, 3 H, CH₃), 1.44 (s, 3 H, CH₃), 1.47 (s, 3 H, CH₃), 1.50 (s, 6 H, 2 × CH₃), 1.53 (s, 3 H, CH₃), 1.54 (s, 6 H, $2 \times CH_3$), 3.12 (dd, 1 H, J = 14.0 and 7.4 Hz, A of ABX, PhCH₂CH), 3.17 (dd, 1 H, J = 14.0 and 7.4 Hz, B of ABX, PhCH₂CH), 4.21 (d, 2 H, J = 12.6 Hz, A of AB, ArCH₂N), 4.30 $(d, 2 H, J = 12.6 Hz, B \text{ of AB, ArCH}_2N), 4.54 (q, 1 H, J = 7.4 Hz, PheCH}_2CH), 5.07 (s. 1H, PheCH}_$ NH), 6.40 (s, 1 H, NH), 7.14 (tt, 1 H, J = 7.3 and 1.1 Hz, H_{ar}), 7.20-7.23 (m, 2 H, 2 × H_{ar}), 7.26-7.29 (m, 2 H, 2 × H_{ar}), 7.37 (s, 1 H, NH), 7.37-7.42 (m, 4 H, 4 × H_{ar}), 7.47-7.52 (m, 2 H, $2 \times H_{ar}$), 7.55 (d, 2 H, J = 7.4 Hz, $2 \times H_{ar}$), 7.61 (d, 1 H, J = 7.3 Hz, NH), 8.08 (s, 1 H, NH) ppm. ¹³C NMR (125 MHz, CDCl₃) δ 24.77 (CH₃), 24.83 (2 × CH₃), 25.2 (CH₃), 26.2 (CH₃), 26.3 (CH₃), 26.4 (CH₃), 26.7 (CH₃), 28.0 (3 × CH₃), 37.8 (CH₂), 48.2 (2 × CH₂), 55.3 (CH), 56.7 (C), 57.1 (C), 57.2 (C), 57.6 (C), 80.8 (C), 126.3 (CH), 128.1 (2 × CH), 128.6 (4 × CH), 129.2 (2 × CH), 129.5 (2 × CH), 129.7 (2 × CH), 133.8 (2 × C), 138.0 (C), 140.5 (2 × C), 156.3 (CO), 171.2 (CO), 174.2 (CO), 174.4 (CO), 174.5 (CO), 175.4 (CO) ppm. MS (ES⁺, MeOH): 783.7 ([M+H]⁺, 15%), 805.6 ([M+Na]⁺, 100%). HRMS (ES⁺, MeOH) calcd for $C_{44}H_{59}N_6O_7 = 783.4440$; found 783.4436.

AzeAib₈-(L)-AlaOtBu (2h)

To a suspension of DSC (45 mg, 0.18 mmol) in CH_2Cl_2 (1 mL) was added dropwise at 0 °C a solution of **5h** (100 mg, 0.12 mmol, obtained by hydrogenolysis of **4h** following general procedure A) in CH_2Cl_2 (2 mL). The reaction mixture was stirred overnight at RT and was diluted with CH_2Cl_2 (100 mL). The organic layer was washed with 5% KHSO₄ (2 × 25 mL)

and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, the residue was dissolved in DMF (2 mL) and this solution was added dropwise to a mixture of 1.HCl (28 mg, 0.12 mmol) and DIPEA (0.48 mmol, 85 μ L) in DMF (1 mL) cooled at 0°C. The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed successively with NaHCO₃ (2×30 mL), 5% KHSO₄ (2×30 mL) and brine (30 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 6:4) provided the titled compound (101 mg, 81%) as a colourless solid. mp = 208-211 °C. IR (solid) v_{max} 3287, 2983, 2936,2870, 1735, 1650, 1529, 1454, 1383, 1361, 1289, 1227, 1166 cm⁻¹. $[\alpha]_{D}^{20} = -39.6$ (c = 1.04, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 1.36 (s, 3 H, CH₃), 1.38-1.58 (m, 57 H, $tBu + 16 \times CH_3$), 4.15-4.42 (m, 5 H, $CHCH_3 + 2 \times CH_2Ar$), 5.49 (s, 1 H, N<u>H</u>), 6.61 (s, 1 H, N<u>H</u>), 7.36-7.42 (m, 4 H, 4 × <u>H</u>_{Ar}), 7.45-7.58 (m, 6 H, 4 × <u>H</u>_{Ar} + 2 × N<u>H</u>), 7.65 (s, 1 H, N<u>H</u>), 7.68 (s, 1 H, N<u>H</u>), 7.69 (s, 1 H, N<u>H</u>), 7.76 (s, 1 H, N<u>H</u>), 8.35 (s, 1 H, N<u>H</u>) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 17.0 (CH₃), 22.6-27.6 (m, 16 × CH₃), 28.1 (3 × CH₃), *t*Bu), 48.1 (2 × CH₂), 49.6 (CH), 56.5 (C), 56.65 (C), 56.69 (C), 56.72 (C), 56.84 (C), 56.87 (C), 56.91 (C), 57.5 (C), 80.6 (C), 128.55 (2 × CH), 128.59 (2 × CH), 129.1 (2 × CH), 129.5 (2 × CH), 133.9 (2 × C), 140.5 (2 × C), 156.6 (CO), 172.8 (CO), 174.9 (CO), 175.3 (CO), 175.5 (CO), 175.6 (CO), 175.8 (CO), 176.03 (CO), 176.05 (CO), 176.1 (CO) ppm. MS (ES⁺, MeOH): 1047.7 ([M+H]⁺, 20%), 1069.7 ([M+Na]⁺, 100%). **HRMS** (ES⁺, MeOH) calcd for $C_{54}H_{83}N_{10}O_{11} = 1047.6237$; found 1047.6239.

Aze-Aib₁₂AlaO^tBu (2j)

To a suspension of DSC (23 mg, 0.088 mmol) in CH₂Cl₂ (1 mL) was added dropwise at 0 °C a solution of 5i (74 mg, 0.063 mmol, obtained by hydrogenolysis of 4i following general procedure A) in CH₂Cl₂ (2 mL). The reaction mixture was stirred overnight at RT and was diluted with CH_2Cl_2 (100 mL). The organic layer was washed with 5% KHSO₄ (2 × 25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, the residue was dissolved in DMF (1 mL) and this solution was added dropwise to a mixture of 1·HCl (15 mg, 0.065 mmol) and DIPEA (0.25 mmol, 44 μ L) in DMF (0.5 mL) cooled at 0°C. The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed successively with NaHCO₃ (2×30 mL), 5% KHSO₄ (2×30 mL) and brine (30 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 6:4) gave a mixture of 2i and 2j. Separation by HPLC provided an analytically pure sample of 2j. mp = 283-285 °C. IR (solid) v_{max} 3291, 2984, 2931, 1651, 1531, 1455, 1384, 1362 cm⁻¹. $[\alpha]_{D}^{20} = -21.6$ (c = 0.5, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 8.39 (br s, 1 H, NH), 7.82 (br s, 1H, NH), 7.80 (br s, 1H, NH), 7.76 (m, 4 H, 4 × NH), 7.69 (br s, 1 H, NH), 7.67 (br s, 1 H, NH), 7.57 (br s, 1 H, NH), 7.55 (s, 2 H, $2 \times H_{Ar}$), 7.51 (m, 3 H, $3 \times H_{Ar}$), 7.41 (m, 3 H, $3 \times$ H_{Ar}), 7.40 (br s, 1H, NH), 6.71 (br s, 1 H, NH), 5.63 (br s, 1 H, NH), 4.27 (m, 5 H, 2 × ArCH₂ and CH), 1.56 (m, 9 H, 3 × CH₃), 1.47-1.54 (m, 54 H, 18 × CH₃), 1.45 (s, 3 H, CH₃), 1.43 (s, 12 H, CH₃ + C(CH₃)₃), 1.41 (m, 3 H, CH₃-CH), 1.38 (s, 3 H, CH₃) ppm. ¹³C NMR (101 MHz, CDCl₃) § 176.2 (2 × CO), 176.2 (CO), 176.1 (CO), 176.1 (CO), 176.0 (CO), 175.9 (CO), 175.7 (CO), 175.5 (CO), 175.4 (CO), 175.2 (CO), 174.8 (CO), 172.7 (CO), 156.5 (CO), 140.4 (2 × C), 133.7 (2 × C), 129.3 (2 × CH), 129.0 (2 × CH), 128.5 (2 × CH), 128.4 (2 × CH), 80.4 (C, *t*Bu), 57.4 (C), 56.8 (C), 56.7 (C), 56.7 (C), 56.6 (C), 56.5 (6 × C), 56.4 (C), 49.5 (CH), 48.1 (2 × CH₂), 28.0 (3 × CH₃, tBu), 22.6-27.4 (24 × CH₃), 16.9 (CH₃) ppm. MS (ES⁺, CH_2Cl_2 : 1388.4 (80%, $[(M+H]^+)$, 1411.1 (100%, $[M+Na]^+$).

AzeAib₁₁AlaO^tBu (2i)



2i was obtained as a side product in the synthesis of **2**j. An analytically pure sample of **2i** was isolated by HPLC. **IR** (solid) v_{max} 3273, 2984, 2935, 1738, 1650, 1538, 1455, 1383, 1361 cm⁻¹. $[\alpha]_D^{20} = -20.0$ (c = 0.5, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 8.40 (br s, 1 H, N<u>H</u>), 7.82 (br s, 1 H, N<u>H</u>), 7.79 (br s, 1 H, N<u>H</u>), 7.77 (br s, 1 H, N<u>H</u>), 7.75 (br s, 2 H, 2 × N<u>H</u>), 7.69 (br s, 1 H, N<u>H</u>), 7.67 (br s, 1 H, N<u>H</u>), 7.57 (br s, 1 H, N<u>H</u>), 7.55 (s, 2 H, 2 × <u>H</u>_{Ar}), 7.51 (m, 3 H, 3 × <u>H</u>_{Ar}), 7.40 (br s, 1 H, N<u>H</u>), 6.71 (br s, 1 H, N<u>H</u>), 5.68 (br s, 1 H, N<u>H</u>), 4.28 (m, 5 H, 2 × ArC<u>H</u>₂N + C<u>H</u>), 1.55 (m, 12 H, 4 × C<u>H</u>₃), 1.47-1.53 (m, 45 H, 15 × C<u>H</u>₃), 1.45 (s, 3 H, C<u>H</u>₃), 1.43 (s, 12 H, CH₃ + C(C<u>H</u>₃)₃), 1.40 (m, 3 H, C<u>H</u>₃-CH), 1.37 (s, 3 H, C<u>H</u>₃) ppm. ¹³C NMR (101 MHz, CDCl₃) δ 176.2 (CO), 176.1 (CO), 176.1 (CO), 175.9 (CO), 175.7 (CO), 175.5 (CO), 175.4 (CO), 175.2 (CO), 174.7 (CO), 172.6 (CO), 156.5 (CO), 140.4 (2 × C), 133.8 (2 × C), 129.3 (2 × CH), 128.9 (2 × CH), 128.5 (C), 56.5 (4 × C), 56.4 (C), 49.5 (CH), 48.1 (br, 2 × CH₂), 28.0 (3 × CH₃, *t*Bu), 23.0-27.4 (m, 22 × CH₃), 16.9 (CH₃) ppm. MS (ES⁺, CH₂Cl₂): 1303.1 (95%, [(M+H]⁺), 1325.1 (100%, [M+Na]⁺).

AzeAib₄OtBu (2x)

᠆ᢩ୵ ᡔ᠉ᢩ᠇[᠊]ᡌᢩᠵ᠆ᢅᡌᢩ᠆ᢅᡀᢩᢂᡔ᠆ᠮ

To a suspension of DSC (107 mg, 0.42 mmol) in CH₂Cl₂ (1.5 mL) was added dropwise at 0 °C a solution of 5x (120 mg, 0.29 mmol) in CH₂Cl₂ (3.0 mL). The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (75 mL). The organic layer was washed with 5% KHSO₄ (2×25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, the residue was dissolved in CH₃CN (2.5 mL) and this solution was added dropwise to a mixture of 1·HCl (67 mg, 0.29 mmol) and DIPEA (222 µL, 1.16 mmol) in CH₃CN (1.25 mL) cooled at 0°C. The reaction mixture was stirred overnight at RT and was diluted with CH₂Cl₂ (50 mL). The organic layer was washed successively with 5% KHSO₄ (2 \times 15 mL), NaHCO₃ (2 \times 15 mL) and brine (15 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 1:1) provided the tilted compound (146 mg, 79%) as a colourless solid. mp = 192-195 °C. IR (solid) v_{max} 3304, 2981, 2934, 1730, 1629, 1520, 1454, 1383, 1362, 1229, 1145 cm⁻¹. ¹H NMR (400 MHz, CDCl₃) δ 1.39 (s, 6 H, 2 × CH₃), 1.42 (s, 9 H, *t*Bu), 1.47 (s, 6 H, 2 × CH₃), 1.51 (s, 6 H, 2 × CH₃), 1.56 (s, 6 H, 2 × CH₃), 4.24 (s, 4 H, 2 × ArCH₂N), 4.87 (s, 1H, NH), 6.35 (s, 1 H, NH), 7.30 (s, 1 H, NH), 7.37-7.42 (m, 4 H, 4 × H_{ar}), 7.46-7.52 (m, 2 H, 2 × H_{ar}), 7.55 (d, 2 H, J = 7.3 Hz, 2 × H_{ar}), 7.77 (s, 1 H, NH) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 24.9 (2 × CH₃), 25.6 (2 × CH₃), 25.7 (2 × CH₃), 25.9 (2 × CH₃), 28.0 (3 × CH₃), 48.1 (2 × CH₂), 56.2 (C), 56.8 (C), 56.9 (C), 57.6 (C), 80.0 (C), 128.61 (2 × CH), 128.63 (2 × CH), 129.2 (2 × CH), 129.5 (2 × CH), 133.7 (2 × C), 140.4 (2 × C), 156.0 (CO), 173.1 (CO), 173.9 (CO), 174.2 (CO), 174.4 (CO) ppm. MS (ES⁺, MeOH): 658.5 $([M+Na]^+, 100\%)$. **HRMS** (ES⁺, MeOH) calcd for C₃₅H₅₀N₅O₆ = 636.3756; found 636.3750.

N₃Aib₄-(L)-AlaNH*t*Bu (4a)

To a mixture of EDC·HCl (900 mg, 4.70 mmol), HOBt·H₂O (719 mg, 4.70 mmol) and **3** (1.39 g, 3.62 mmol) in CH₂Cl₂ (25 mL) was added dropwise at 0 °C DIPEA (1.26 mL, 7.24 mmol). The reaction mixture was stirred at RT for 30 min and a solution of NH₂-(L)-AlaNHtBu (627 mg, 4.35 mmol) in CH₂Cl₂ (5 mL) was added dropwise. The reaction mixture was stirred at RT for 4 days and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed successively with 5% KHSO₄ (2×50 mL), NaHCO₃ (2×50 mL) and brine (50 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, MeOH/CH₂Cl₂ 3:97 \rightarrow 5:95) provided the tilted compound (1.74 g, 94%) as a colourless solid. mp = 214 °C. IR (solid) v_{max} 3307, 2977, 2936, 2111, 1648, 1526, 1454, 1382, 1362, 1221 cm⁻¹. $[\alpha]_D^{20} = +28.0$ (c = 1.03, MeOH). ¹H **NMR** (500 MHz, CDCl₃) δ 1.37 (s, 12 H, *t*Bu + CH₃), 1.41 (d, 3 H, *J* = 7.3 Hz, CH₃CH), 1.45 (s, 6 H, 2 × CH₃), 1.47 (s, 3 H, CH₃), 1.48 (s, 3 H, CH₃), 1.53 (s, 3 H, CH₃), 1.55 (s, 3 H, CH₃), 1.57 (s, 3 H, CH₃), 4.33 (quin, 1 H, J = 7.5 Hz, CH₃CH), 6.18 (s, 1H, NH), 6.77 (s, 1 H, NH), 6.91 (s, 1 H, NH), 7.27 (s, 1 H, NH), 7.45 (d, 1 H, J = 7.9 Hz, NH) ppm. ¹³C NMR (125) MHz, CDCl₃) δ 17.3 (CH₃), 23.46 (CH₃), 23.49 (CH₃), 23.7 (CH₃), 24.3 (CH₃), 24.6 (CH₃), 26.4 (CH₃), 27.4 (CH₃), 27.5 (CH₃), 28.8 (3 × CH₃), 50.1 (CH), 51.1 (C), 56.9 (C), 57.1 (C), 57.3 (C), 64.1 (C), 172.5 (CO), 173.3 (2 \times CO), 173.6 (CO), 174.5 (CO) ppm. MS (ES⁺, MeOH): 511.5 ([M+H]⁺, 20%), 533.5 ([M+Na]⁺, 100%). HRMS (ES⁺, MeOH) calcd for $C_{23}H_{42}N_8O_5Na = 533.3170$; found 533.3183.

N₃Aib₄-(L)-PheNH*t*Bu (4b)



To a mixture of HOBt·H₂O (204 mg, 1.33 mmol) and 3 (397 mg, 1.03 mmol) in CH₂Cl₂ (20 mL) was added dropwise at 0 °C EDC (200 µL, 1.13 mmol). The reaction mixture was stirred at RT for 30 min and a solution of NH₂-(L)-PheNHtBu (273 mg, 1.24 mmol) in CH₂Cl₂ (5 mL) and TEA (287 µL, 2.06 mmol) were successively added dropwise. The reaction mixture was stirred at RT for 2 days and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed successively with 5% KHSO₄ (2×40 mL), NaHCO₃ (2×40 mL) and brine (20 mL) and was dried over MgSO4. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 4:6) followed by crystallisation from CH₃CN provided the tilted compound (323 mg, 53%) as a colourless solid. mp = 212 °C. IR (solid) v_{max} 3309, 2979, 2939, 2105, 1653, 1526, 1454, 1383, 1362, 1282, 1222, 1167 cm⁻¹. $[\alpha]_{D}^{20} = +22.3^{\circ}$ (c = 0.52, MeOH). ¹H NMR (500 MHz, CDCl₃) δ 1.11 (s, 3 H, CH₃), 1.34 (s, 3 H, CH₃), 1.40 (s, 9 H, tBu), 1.455 (s, 3 H, CH₃), 1.46 (s, 3 H, CH₃), 1.47 (s, 6 H, 2 × CH₃), 1.52 (s, 3 H, CH₃), 1.53 (s, 3 H, CH₃), 2.88 (dd, 1 H, *J* = 12.0 and 14.5 Hz, PheCH₂CH), 3.61 (dd, 1 H, J = 3.2 and 14.5 Hz, PheCH₂CH), 4.55 (ddd, 1 H, J = 11.9, 8.7 and 3.2 Hz, PheCH₂C<u>H</u>), 6.23 (s. 1H, N<u>H</u>), 6.91 (s, 1 H, N<u>H</u>), 7.00 (s, 1 H, N<u>H</u>), 7.10 (t, 1 H, J = 7.3 Hz, H_{ar}), 7.16 (t, 2 H, J = 7.3 Hz, $2 \times$ H_{ar}), 7.25-7.28 (m, 3 H, NH + $2 \times$ H_{ar}), 7.32 (d, 1 H, J = 8.7 Hz, NH) ppm. ¹³C NMR (125 MHz, CDCl₃) δ 23.19 (CH₃), 23.24 (CH₃), 23.4 (CH₃), 24.1 (CH₃), 24.4 (CH₃), 26.5 (CH₃), 26.8 (CH₃), 27.4 (CH₃), 28.7 (3 × CH₃), 37.2 (CH₂), 51.2 (C), 55.3 (CH), 56.6 (C), 57.0 (C), 57.1 (C), 63.9 (C), 126.0 (CH), 128.0 (2 × CH), 129.1 (2 × CH), 139.1 (C), 171.0 (CO), 173.1 (CO), 173.2 (CO), 173.4 (CO), 174.6 (CO) ppm. MS (ES⁺, MeOH): 587 ([M+H]⁺, 100%), 609 ([M+Na]⁺, 75%). HRMS $(ES^+, MeOH)$ calcd for $C_{29}H_{47}N_8O_5 = 587.3664$; found 587.3654.

N₃-Aib₄-(L)-*t*LeuNH*t*Bu (4c)

$$^{N_3} \times \overset{O}{\xrightarrow{}}_{H} \overset{V}{\xrightarrow{}}_{O} \overset{H}{\xrightarrow{}}_{O} \overset{O}{\xrightarrow{}}_{H} \overset{V}{\xrightarrow{}}_{O} \overset{H}{\xrightarrow{}}_{O} \overset{O}{\xrightarrow{}}_{H} \overset{V}{\xrightarrow{}}_{H} \overset{V}{\xrightarrow{}}_{O} \overset{H}{\xrightarrow{}}_{H} \overset{V}{\xrightarrow{}}_{H} \overset{V}{$$

To a mixture of HOBt·H₂O (26 mg, 0.170 mmol), EDC·HCl (32 mg, 0.167 mmol) and 3 (50 mg, 0.130 mmol) in CH₂Cl₂ (1 mL) was added dropwise at 0 °C DIPEA (67 µL, 0.387 mmol). The reaction mixture was stirred at RT for 30 min and NH₂-(L)-tLeu-NHtBu (29 mg, 0.156 mmol) was added portionwise. The reaction mixture was stirred at RT for 2 days and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed successively with 5% KHSO₄ (2 \times 40 mL), NaHCO₃ (2 \times 40 mL) and brine (20 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 6:4) provided the tilted compound (56 mg, 78 %) as a colourless solid. **mp** = 220-222 °C. **IR** (solid) v_{max} 3374, 3335, 2969, 2937, 2873, 2112, 1683, 1642, 1525, 1454, 1383, 1361, 1219, 1172 cm⁻¹. $[\alpha]_D^{20} = -4.1^\circ$ (c = 0.49, MeOH). ¹H NMR (400 MHz, CDCl₃) δ 1.10 (s, 9 H, 3 × CH₃, *t*Bu), 1.36 (s, 9 H, 3 × CH₃, *t*Bu), 1.37 (s, 3 H, CH₃), 1.46 (s, 3 H, CH₃), 1.47 (s, 3 H, CH₃), 1.48 (s, 3H, CH₃), 1.49 (s, 3 H, CH₃), 1.53 (s, 6 H, $2 \times CH_3$), 1.55 (s, 3 H, CH₃), 4.03 (d, 1 H, J = 8.1 Hz, CHC(CH₃)₃), 6.12 (s, 1 H, NH), 6.51 (s, 1 H, NH), 6.93 (s, 3 H, CH₃), 7.11 (d, 1 H, *J* = 8.1 Hz, NH), 7.35 (s, 1 H, NH) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 23.63 (CH₃), 23.65 (CH₃), 23.8 (CH₃), 24.3 (CH₃), 24.6 (CH₃), 26.5 (CH₃), 27.38 (CH₃), 27.44 (3 × CH₃, *t*Bu), 27.6 (CH₃), 28.8 (3 × CH₃, *t*Bu), 34.0 (C), 51.2 (C), 56.9 (C), 57.2 (C), 57.3 (C), 63.0 (CH), 64.1 (C), 170.5 (CO), 172.6 (CO), 173.1 (CO), 173.3 (CO), 174.6 (CO) ppm. **MS** (ES⁺, MeOH): 553.5 ([M+H]⁺, 100 %). **HRMS** (ES⁺, MeOH) calcd for $C_{26}H_{49}N_8O_5 = 553.3820$; found 553.3817.

N₃Aib₄-(L)-AlaOtBu (4d)



To a mixture of EDC·HCl (259 mg, 1.35 mmol), HOBt·H₂O (206 mg, 1.35 mmol) and **3** (400 mg, 1.04 mmol) in CH₂Cl₂ (10 mL) was added dropwise at 0 °C DIPEA (652 µL, 3.75 mmol). The reaction mixture was stirred at RT for 30 min and HCl·NH₂-(L)-AlaOtBu (227 mg, 1.25 mmol) was added portion wise. The reaction mixture was stirred at RT for 3 days and was diluted with CH₂Cl₂ (75 mL). The organic layer was washed successively with 5% KHSO₄ (2 \times 25 mL), NaHCO₃ (2 \times 25 mL) and brine (25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 5:5 \rightarrow 7:3) provided the tilted compound (457 mg, 86%) as a colourless solid. **mp** = 161-162 °C. **IR** (solid) v_{max} 3346, 3223, 2980, 2936, 2875, 2110, 1738, 1695, 1644, 1515, 1455, 1382, 1364, 1304, 1260, 1223, 1153 cm⁻¹. $[\alpha]_{D}^{20} = -51.0$ (c = 1.02, MeOH). ¹H NMR (400 MHz, CDCl₃) δ 1.38 (s, 3 H, CH₃), 1.39 (d, 3 H, J = 7.2 Hz, CH₃), 1.42 (s, 9 H, 3 × CH₃), 1.45 (s, 3 H, CH₃), 1.47 (s, 3 H, CH₃), 1.48 (s, 3 H, CH₃), 1.50 (s, 3 H, CH₃), 1.523 (s, 3 H, CH₃), 1.526 (s, 3 H, CH₃), 1.53 (s, 3 H, CH₃), 4.33 (quin, 1 H, J = 7.2 Hz, CH₃CH), 6.22 (s, 1 H, NH), 6.91 (s, 1 H, NH), 7.16 (s, 1 H, NH), 7.24 (d, 1 H, J= 7.0 Hz, NH) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 17.4 (CH₃), 24.2 (2 × CH₃), 24.3 (CH₃), 24.4 (CH₃), 24.5 (CH₃), 25.8 (CH₃), 26.7 (CH₃), 26.8 (CH₃), 28.1 (3 × CH₃), 49.2 (CH), 57.0 (C), 57.08 (C), 57.13 (C), 64.2 (C), 80.8 (C), 172.5 (CO), 172.8 (CO), 172.9 (CO), 173.0 (CO), 174.6 (CO) ppm. **MS** (ES⁺, MeOH): 534.5 ([M+Na]⁺, 100%). **HRMS** (ES⁺, MeOH) calcd for $C_{23}H_{41}N_7O_6Na = 534.3011$; found 534.3007.

N₃Aib₄-(D)-AlaOtBu (4e)

To a mixture of EDC•HCl (193 mg, 1.01 mmol), HOBt•H₂O (155 mg, 1.01 mmol) and **3** (300 mg, 0.78 mmol) in CH₂Cl₂ (8 mL) was added dropwise at 0 °C DIPEA (407 μ L, 2.34 mmol). The reaction mixture was stirred at RT for 30 min and HCl•NH₂-(D)-AlaOtBu (170 mg, 0.94

mmol) was added portion wise. The reaction mixture was stirred at RT for 2 days and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed successively with 5% KHSO₄ (2 × 30 mL), NaHCO₃ (2 × 30 mL) and brine (30 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 5:5 \rightarrow 7:3) provided the titled compound (372 mg, 93%) as a colourless solid. Spectroscopic data of **4e** are identical to those of **4d**. $[\alpha]_{D}^{20}$ = +51.4 (c = 1.02, MeOH).

N₃Aib₄-(L)-ValOtBu (4f)



To a mixture of HOBt·H₂O (52 mg, 0.33 mmol), EDC·HCl (64 mg, 0.33 mmol) and **3** (100 mg, 0.26 mmol) in CH₂Cl₂ (3 mL) was added dropwise at 0 °C DIPEA (135 μ L, 0.78 mmol). The reaction mixture was stirred at RT for 30 min and HCl·NH₂-(L)-ValOtBu (66 mg, 0.31 mmol) was added portion wise. The reaction mixture was stirred at RT for 2 days and was diluted with CH₂Cl₂ (100 mL). The organic layer was washed successively with 5% KHSO₄ (2 × 40 mL), NaHCO₃ (2 × 40 mL) and brine (20 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 6:4) provided the titled compound (134 mg, 95 %) as a colourless solid. **mp** = 160-162 °C. **IR** (solid) v_{max} 3325, 2978, 2936, 2874, 2111, 1715, 1650, 1518, 1457, 1382, 1364, 1286, 1259, 1223, 1159 cm⁻¹. [α] $_{D}^{20}$ = -32.8 (c = 0.5, MeOH). ¹H NMR (400 MHz, CDCl₃) δ 0.96 (d, 6 H, *J* = 6.8 Hz, CH(CH₃)₂), 1.41 (s, 3 H, CH₃), 1.44 (s, 9 H, *t*Bu), 1.46 (s, 3 H, CH₃), 1.49 (s, 3 H, CH₃), 1.502 (s, CH₃), 1.504 (s, 3 H, CH₃), 1.53 (s, 9 H, 3 × CH₃), 2.18 (oct, 1 H, *J* = 6.4 Hz, CH(CH₃)₂), 4.27 (dd, 1 H, *J* = 6.0 and 8.2 Hz, CH(CH(CH₃)₂), 6.16 (s. 1H, NH), 6.87 (s, 1 H, NH), 7.09 (d, 1 H, *J* = 8.2 Hz, NH), 7.21 (s, 1 H, NH) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 18.3 (CH₃, *i*Pr), 19.2 (CH₃, *i*Pr), 24.4 (CH₃),

24.5 (CH₃), 24.6 (3 × CH₃), 25.6 (CH₃), 26.5 (CH₃), 26.6 (CH₃), 28.2 (3 × CH₃, *t*Bu), 30.8 (CH, *i*Pr), 57.0 (C), 57.2 (2 × C), 58.8 (CH), 64.2 (C), 80.9 (C), 171.2 (CO), 172.6 (CO), 172.7 (CO), 172.9 (CO), 174.9 (CO) ppm. **MS** (ES⁺, MeOH): 540.4 ([M+H]⁺, 100 %), 562.5 ([M+Na]⁺, 30 %). **HRMS** (ES⁺, MeOH) calcd for C₂₅H₄₆N₇O₆ = 540.3504; found 540.3496.

N₃Aib₄-(L)-PheOtBu (4g)



To a mixture of HOBt·H₂O (63 mg, 0.41 mmol) and **3** (120 mg, 0.31 mmol) in CH₂Cl₂ (6 mL) was added dropwise at 0 °C EDC (61 µL, 0.34 mmol). The reaction mixture was stirred at RT for 30 min and HCl·NH₂-(L)-PheOtBu (178 mg, 0.69 mmol) and TEA (131 µL, 0.94 mmol) were successively added. The reaction mixture was stirred at RT for 3 days and was diluted with CH_2Cl_2 (50 mL). The organic layer was washed successively with 5% KHSO₄ (2 × 25 mL), NaHCO₃ (2×25 mL) and brine (25 mL) and was dried over MgSO₄. After evaporation of the solvent under reduced pressure, purification of the crude by column chromatography (SiO₂, EtOAc/CH₂Cl₂ 4:6) provided the titled compound (156 mg, 85%) as a colourless solid. mp = 68-72 °C. IR (solid) v_{max} 3320, 2982, 2934, 2111, 1722, 1651, 1516, 1455, 1382, 1364, 1257, 1223, 1152 cm⁻¹. $[\alpha]_{D}^{20} = -4.0^{\circ}$ (c = 0.50, MeOH). ¹H NMR (500 MHz, CDCl₃) δ 1.34 (s, 9 H, *t*Bu), 1.41 (s, 3 H, CH₃), 1.42 (s, 3 H, CH₃), 1.46 (s, 3 H, CH₃), 1.48 (s, 3 H, CH₃), 1.49 (s, 6 H, $2 \times CH_3$), 1.52 (s, 3 H, CH₃), 1.53 (s, 3 H, CH₃), 3.09 (dd, 1 H, J = 14.2 and 7.2 Hz, A of ABX, PheCH₂CH), 3.11 (dd, 1 H, J = 14.2 and 7.2 Hz, B of ABX, PheCH₂CH), 4.59 (q, 1 H, J = 7.2 Hz, PheCH₂CH), 6.22 (s. 1H, NH), 6.91 (s, 1 H, NH), 7.14 (s, 1 H, NH), 7.14-7.18 (m, 1 H, <u>Har</u>), 7.20-7.28 (m, 5 H, N<u>H</u> + 4 × <u>Har</u>) ppm. ¹³C NMR (125 MHz, CDCl₃) δ 24.4 (CH₃), 24.5 (CH₃), 24.7 (CH₃), 24.8 (CH₃), 25.0 (CH₃), 25.3 (CH₃), 26.0 (CH₃), 26.1 (CH₃), 28.0 (3 × CH₃), 37.9 (CH₂), 54.8 (CH), 57.0 (C), 57.1 (C), 57.2 (C), 64.2 (C), 81.3 (C),

126.5 (CH), 128.2 (2 × CH), 129.7 (2 × CH), 137.5 (C), 171.0 (CO), 172.8 (CO), 172.9 (2 × CO), 174.7 (CO) ppm. **MS** (ES⁺, MeOH): 588 ([M+H]⁺, 80%), 610 ([M+Na]⁺, 100%). **HRMS** (ES⁺, MeOH) calcd for C₂₉H₄₆N₇O₆ = 588.3504; found 588.3498.

N₃Aib₈-(L)-AlaOtBu (4h)

5d (414 mg, 0.85 mmol) and the azlactone (312 mg, 0.85 mmol), synthesized respectively from **4d** and **3** following general procedure A and B, were dissolved in dry acetonitrile (7 mL) and the mixture was heated at reflux for 5 days. The solvent was then evaporated under reduced pressure and purification of the crude by column chromatography (EtOAc/ CH₂Cl₂ 7:3) provided the title compound (455 mg, 63%) as a white solid. **mp** = 229-230 °C. **IR** (solid) v_{max} 3303, 2983, 2938, 2873, 2109, 1736, 1657, 1644, 1526, 1455, 1383, 1363, 1276, 1227, 1168, 1153 cm⁻¹. [α] $_{D}^{20}$ = -41.4 (c = 0.55, MeOH). ¹H NMR (400 MHz, CDCl₃) δ 1.40 (s, 3 H, CH₃), 1.41-1.52 (m, 45 H, 15 × CH₃), 1.53-1.59 (m, 12 H, 4 × CH₃), 4.35 (quin, 1 H, J = 7.1 Hz, C<u>H</u>CH₃), 6.21 (s, 1 H, N<u>H</u>), 6.98 (s, 1 H, N<u>H</u>), 7.43 (s, 1 H, N<u>H</u>), 7.49-7.54 (m, 2 H, 2 × N<u>H</u>), 7.56 (s, 1 H, N<u>H</u>), 7.57 (s, 1 H, N<u>H</u>), 7.61 (s, 1 H, N<u>H</u>) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 175.8 (CO), 175.5 (CO), 175.4 (2 × CO), 174.7 (CO), 174.4 (CO), 173.7 (CO), 173.4 (CO), 172.7 (CO), 80.5 (C), 64.0 (C), 57.1 (C), 57.0 (C), 56.95 (C), 56.91 (C), 56.8 (2 × C), 56.7 (C), 49.6 (CH), 28.1 (3 × CH₃, *t*Bu), 23.0-27.3 (m, 16 × CH₃), 17.1 (CH₃) ppm. MS (ES⁺, MeOH): 852.7 ([M+H]⁺, 90%), 874.7 ([M+Na]⁺, 100%). HRMS (ES⁺, MeOH) calcd for C₃₉H₆₉N₁₁O₁₀Na = 874.5127; found 874.5084.

N₃Aib₁₂-(L)-AlaOtBu (4j)

$$N_{3} \xrightarrow{O}_{\mathcal{H}} \xrightarrow{O}_{\mathcal{H}$$

5h (120 mg, 0.145 mmol) and the azlactone (58 mg, 0.16 mmol), synthesized respectively from 4h and 3 following general procedure A and B, were dissolved in dry acetonitrile (3 mL) and the mixture was heated at reflux for 4 days under N₂ atmosphere. The solvent was then evaporated under reduced pressure and the crude was purified by column chromatography (EtOAc/DCM from 6:4 to 7:3) to provide the title compound (78 mg, 45%) as a white solid. mp > 300 °C. IR (solid) v_{max} 3287, 2984, 2936, 2872, 2113, 1660, 1530, 1455, 1383, 1362, 1294, 1227, 1168 cm⁻¹. $[\alpha]_{D}^{20} = -23.7$ (c = 0.54, CH₂Cl₂). ¹H NMR (400 MHz, CDCl₃) δ 1.41 (s, 3 H, CH₃), 1.42-1.53 (m, 69 H, $tBu + 20 \times CH_3$), 1.53-1.60 (m, 12 H, $4 \times CH_3$), 4.34 (quin, 1 H, J = 7.1 Hz, CH₃CH), 6.33 (s, 1 H, NH), 7.07 (s, 1 H, NH), 7.47 (s, 1 H, NH), 7.54-7.57 (m, 2 H, 2 × NH), 7.646 (s, 1 H, NH), 7.654 (s, 1 H, NH), 7.661 (s, 1 H, NH), 7.67 (s, 1 H, N<u>H</u>), 7.71 (s, 1 H, N<u>H</u>), 7.73 (s, 2 H, $2 \times N$ <u>H</u>) ppm. ¹³C NMR (100 MHz, CDCl₃) δ 17.1 (CH₃), 22.9-27.0 (24 × CH₃), 28.1 (3 × CH₃, *t*Bu), 49.5 (CH), 56.6-56.7 (m, 4 × C), 56.7-56.8 $(m, 3 \times C), 56.94 (C), 56.97 (2 \times C), 57.1 (C), 64.1 (C), 80.5 (C), 172.8 (CO), 173.46 (CO), 1$ 173.53 (CO), 174.3 (CO), 174.8 (CO), 175.4 (CO), 175.6 (CO), 175.7 (CO), 175.9 (CO), 176.0 (CO), 176.08 (CO), 176.14 (CO), 176.16 (CO) ppm. MS (ES⁺, MeOH): 1192.8 $([M+H]^+, 35\%)$, 1214.8 $([M+Na]^+, 100\%)$. **HRMS** (ES⁺, MeOH) calcd for C₅₅H₉₇N₁₅O₁₄Na = 1214.7237; found 1214.7215.



Scheme 1: Synthesis of 6a and 6b.

Aze-Aib^u-Aib^u-Val^u-Ala^u-Leu^u-NH*i*Pr (6a)

Boc-protected oligourea **7a** (40 mg, 0.059 mmol) was dissolved in TFA (400 μ L) and stirred for 45 min. The reaction mixture was then concentrated under reduced pressure and the resulting residue was co-evaporated 3 times with cyclohexane. The crude mixture was dissolved in CH₂Cl₂ and treated with 1 M K₂CO₃ aqueous solution and brine. The organic layer was then dried over MgSO₄ and evaporated. The crude product was dissolved in a stirred solution of **AzeCl** (20 mg, 0.077 mmol, synthesized from **1** following general procedure C) in anhydrous acetonitrile (150 μ L). Et₃N (11 μ L) and a catalytic amount of DMAP were added and the resulting mixture was refluxed overnight. The reaction mixture was then diluted with DCM and quenched with water. The organic layer was separated and the aqueous layer was extracted twice with EtOAc. The combined organic extracts were dried

MgSO₄, filtered and concentrated *in-vacuo*. Purification by flash column over chromatography (CH₂Cl₂-MeOH (v/v), 90:10) yielded the title compound as a white solid (20 mg, 0.023 mmol, 39%). mp = 170-172 °C. ¹H NMR (500 MHz, CD₃OH) δ 7.54 (2H, dd, J = 0.9 and 7.6, 2 x CH_{ar}), 7.48 (2H, dt, J = 1.5 and 7.3, 2 x CH_{ar}), 7.43 (2H, dd, J = 1.1 and 7.4, 2 x CH_{ar}), 7.38 (2H, dt, J = 1.3 and 7.3, 2 x CH_{ar}), 7.30 (1H, t, J = 5.2, NH_{Aib2}), 6.44 (1H, s, $N'H_{Aib1 \text{ or } Aib2}$, 6.40 (1H, s, $N'H_{Aib1 \text{ or } Aib2}$), 6.38 (1H, dd, J = 2.8 and 9.9, NH_{Ala}), 6.25-6.19 (2H, m, N H_{Val} and N H_{Aibl}), 6.17 (1H, d, J = 10.7, N' H_{Val}), 5.92 (1H, dd, J = 5.2 and 7.2, NH_{Leu} , 5.82 (1H, d, J = 10.0, N' H_{Ala}), 5.67 (1H, d, J = 7.8, NH_{iPr}), 5.47 (1H, d, J = 9.6, N' H_{Leu}), 4.24 (2H, d, $J = 13.0, 2 \times CH_AH_B$, A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), 4.24 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A part of AB pattern), 4.17 (2H, d, $J = 13.0, 2 \times CH_AH_B$), A pattern), A patt CH_AH_B, B part of AB pattern), 4.07-3.96 (1H, m, NCH_{Leu}), 3.96-3.86 (1H, m, NCH_{Ala}), 3.77 $(1H, hept, J = 7.4, NCH_{iPr}), 3.74-3.68 (1H, m, NCH_{Val}), 3.68-3.63 (1H, m, NCH_AH_{BAibl}), 3.60$ (1H, ddd, J = 2.7, 10.6 and 16.5, NCH_AH_{BAla}), 3.52 (1H, ddd, J = 3.6, 9.7 and 13.7, NCH_AH_{BVal} , 3.48-3.35 (3H, m, NCH_AH_{BLeu} and NCH_{2Aib2}), 3.26 (1H, dd, J = 9.9 and 13.2, NCH_AH_{BAib1} , 2.52-2.26 (3H, m, NCH_AH_{BVal} , NCH_AH_{BLeu} and NCH_AH_{BAla}), 1.66 (1H, non, J $= 7.0, CH_{Leu}$, 1.52 (1H, oct, $J = 6.8, CH_{Val}$), 1.34 (3H, s, $CH_{3Aib1 \text{ or } Aib2}$), 1.31 (3H, s, $CH_{3Aib1 \text{ or } Aib2}$) A_{ib2}), 1.27 (6H, s, $CH_{3Aib1 \text{ or } Aib2}$), 1.19 (2H, t, J = 7.3, CH_{2Leu}), 1.12 (3H, d, J = 6.6, CH_{3iPr}), 1.11 (3H, d, J = 6.6, CH_{3iPr}), 1.03 (3H, s, $CH_{3Aib1 \text{ or } Aib2}$), 1.01 (3H, d, J = 6.9, CH_{3Ala}), 0.91 $(3H, d, J = 6.8, CH_{3Leu}), 0.87 (3H, d, J = 6.7, CH_{3Leu}), 0.84 (3H, d, J = 6.9, CH_{3Val}), 0.80 (3H,$ d, J = 6.9, CH_{3Val}) ppm. ¹³C NMR (125 MHz, CD₃OH) δ 162.8 (C=O), 161.4 (C=O), 160.8 (C=O), 160.5 (2 x C=O), 159.6 (C=O), 141.8 (2 x = C_{Ar}), 135.4 (2 x = C_{Ar}), 130.5 (2 x = CH_{Ar}), 129.7 (2 x = CH_{Ar}), 129.3 (2 x = CH_{Ar}), 128.9 (2 x = CH_{Ar}), 55.4 (N $C_{\rho}H_{Val}$), 54.2 ($C_{Aib1 \text{ or } Aib2}$), 53.7 (*C_{Aib1 or Aib2}*), 52.5 (N*C_a*H_{2Aib2}), 46.7 (2 x NCH₂Ar), 48.6 (N*C_a*H_{2Ala}), 48.5 (N*C_p*H_{Leu}), 47.4 $(NC_{a}H_{2Aib1} \text{ and } NC_{a}H_{2Leu}), 47.1 (NC_{b}H_{Ala}), 43.8 (NC_{a}H_{2Val}), 43.1 (NCH_{iPr}), 42.9 (NC_{r}H_{2Leu}),$ 31.7 (C₁H_{Val}), 26.8 (C₁H_{3Aib1 or Aib2}), 26.7 (C₁H_{3Aib1 or Aib2}), 26.3 (C₁H_{3Aib1 or Aib2}), 26.2 (C₂H_{Leu}), 25.5 (C_rH_{3Aib1 or Aib2}), 23.5 (CH_{3iPr}), 23.5 (CH_{3iPr}), 23.5 (CH_{3iPr}), 23.5 (C_sH_{3Leu}), 22.5 (C_sH_{3Leu}), 19.7 (C_sH_{3Val}),

18.8 ($C_{s}H_{3Ala}$), 18.3 ($C_{s}H_{3Val}$) ppm. **IR** (film) v 3343 (NH broad), 2965, 2930, 2868 (C-H), 1632 (C=O urea), 1220, 772 cm⁻¹. $[\alpha]_{D}^{20} = +$ 8.2 (c = 0.50, TFE). **HRMS (ESI⁺)**: *m/z* calcd for C₄₅H₇₅O₆N₁₂ [M+H]⁺ 879.5927, found 879.5928.

Residue	NH	N'H	α	β	γ	δ	3	CH ₂	СН	Δδ(Ηα)
Aze								4.24 / 4.17		
Aib ₂	7.30	6.44	3.45 / 3.40		/					0.05
Aib ₁	6.19	or 6.40	3.68 / 3.28		/					0.40
Val	6.24	6.17	3.53 / 2.41	3.71	1.52	0.80 / 0.84				1.12
Ala	6.38	5.82	3.61 / 2.37	3.93	1.01					1.24
Leu	5.92	5.47	3.44 / 2.43	4.02	1.20	1.66	0.91 / 0.87			1.01
iPr	5.67							1.12 / 1.11	3.77	

Aze-Aib^u-Aib^u-Aib^u-Val^u-Ala^u-Leu^u-NH*i*Pr (6b)



Boc-protected oligourea **7b** (62 mg, 0.071 mmol) was dissolved in TFA (600 μ L) and stirred for 45 min. The reaction mixture was then concentrated under reduced pressure and the resulting residue was coevaporated 3 times with cyclohexane. The crude mixture was dissolved in CH₂Cl₂ and treated with 1 M K₂CO₃ aqueous solution and brine. The organic layer was then dried over MgSO₄ and evaporated. The crude product was dissolved in a stirred solution of **AzeCl** (24 mg, 0.092 mmol, synthesized from **1** following general procedure C) in acetonitrile (180 μ L). Et₃N (600 μ L) and a catalytic amount of DMAP were added and the resulting mixture was refluxed overnight. The reaction mixture was then diluted with DCM and quenched with water. The organic layer was separated and the aqueous layer was extracted twice with EtOAc. The combined organic extracts were dried over MgSO₄, filtered and concentrated *in-vacuo*. Purification by flash column chromatography (CH₂Cl₂-MeOH (v/v), 90:10) yielded the title compound as a white solid (49 mg, 0.049 mmol, 69.5%). **mp** = 192-194 °C; ¹**H NMR** (500 MHz, CD₃OH) δ 7.55-7.51 (2H, m, 2 x CH_{ar}), 7.50-7.45 (2H, m, 2 x CH_{ar}), 7.44 -7.41 (2H, m, 2 x CH_{ar}), 7.40-7.34 (2H, m, 2 x CH_{ar}), 7.25 (1H, t, J = 5.1, NH_{Aib3}), 6.43 (1H, s, $N'H_{Aib1 \text{ or } Aib2 \text{ or } Aib3}$), 6.38 (1H, dd, J = 2.7 and 9.9, NH_{Ala}), 6.25 (1H, dd, J = 3.0 and 9.5, NH_{Val}), 6.20-6.17 (2H, m, NH_{Aib1} and N'H_{Val}), 6.12 (2H, brs, N' H_{Aib1} and/or Aib2 and/or Aib3), 6.03 (1H, t, J = 6.1, N H_{Aib2}), 5.93 (1H, t, J = 5.4, N H_{Leu}), 5.83 (1H, d, J = 10.0, N' H_{Ala}), 5.69 (1H, d, J = 7.8, N H_{iPr}), 5.49 (1H, d, J = 9.5, N' H_{Leu}), 4.21 (4H, AB system), 4.07-3.97 (1H, m, NCH_{Leu}), 3.97-3.86 (1H, m, NCH_{Ala}), 3.79 (1H, hept, J =6.7, NCH_{iPr}), 3.75-3.66 (1H, m, NCH_{Val}), 3.66-3.48 (3H, m, NCH_AH_{BAib1}, NCH_AH_{BAla} and NCH_AH_{BVal} , 3.47-3.33 (4H, m, NCH_AH_{BLeu} , NCH_{2Aib3} and NCH_AH_{BAib2}), 3.29 (1H, dd, J = 7.5and 13.3, NCH_A H_{BAib2}), 3.21 (1H, dd, J = 9.8 and 13.1, NCH_A H_{BAib1}), 2.50-2.39 (2H, m, NCH_AH_{BVal} and NCH_AH_{BLeu} , 2.39-2.28 (1H, m, NCH_AH_{BAla}), 1.67 (1H, non, J = 6.9, CH_{Leu}), 1.59 (1H, oct, J = 6.8, CH_{Val}), 1.28 (9H, s, $CH_{3Aib1 and/or Aib2 and/or Aib3}$), 1.27 (3H, s, $CH_{3Aib1 or Aib2}$ or Aib3), 1.20 (2H, t, J = 7.5, CH_{2Leu}), 1.17 (3H, s, CH_{3Aib1} or Aib2 or Aib3), 1.12 (6H, d, J = 6.6, CH_{3iPr}), 1.04 (3H, s, $CH_{3Aib1 \text{ or } Aib2 \text{ or } Aib3}$), 1.03 (3H, d, J = 7.0, CH_{3Ala}), 0.92 (3H, d, J = 6.7, CH_{3Leu}), 0.91 (3H, d, J = 6.9, CH_{3Leu}), 0.88 (3H, d, J = 6.7, CH_{3Val}), 0.86 (3H, d, J = 7.0, CH_{3Val} ppm. ¹³C NMR (125 MHz, CD₃OH) δ 162.7 (C=O), 161.3 (C=O), 160.7 (2 x C=O), 160.5 (2 x C=O), 159.6 (C=O), 141.7 (2 x = C_{Ar}), 135.4 (2 x = C_{Ar}), 130.5 (2 x = CH_{Ar}), 129.7 $(2 \text{ x} = CH_{Ar}), 129.3 \ (2 \text{ x} = CH_{Ar}), 129.0 \ (2 \text{ x} = CH_{Ar}), 55.5 \ (NC_{P}H_{Val}), 54.2 \ (C_{Aib1 \text{ or } Aib2 \text{ or } Aib3}),$ 53.7 (2 x C_{Aib1 or Aib2 or Aib3}), 52.4 (NC_aH_{2Aib3}), 49.0 (NC_aH_{2Aib2}), 48.6 (2 x NCH₂Ar), 48.5 $(NC_{a}H_{2Ala})$, 48.4 $(NC_{p}H_{Leu})$, 47.4 $(NC_{a}H_{2Aibl}$ and $NC_{a}H_{2Leu})$, 47.1 $(NC_{p}H_{Ala})$, 43.9 $(NC_{a}H_{2Val})$, 43.1 (NCH_{*i*Pr}), 42.9 (NC_{*i*}H_{2Leu}), 31.7 (C_{*i*}H_{Val}), 26.9 (C_{*i*}H_{3Aib1}), 26.5 (C_{*i*}H_{3Aib2}), 26.2 (C_{*i*}H_{Leu}), 26.2 (C_rH_{3Aib1 or 2}), 26.2 (C_rH_{3Aib1 or 2}), 26.0 (C_rH_{3Aib3}), 25.6 (C_rH_{3Aib3}), 23.6 (2 x CH_{3iPr}), 23.5 $(C_{i}H_{3Leu})$, 22.5 $(C_{i}H_{3Leu})$, 20.0 $(C_{s}H_{3Val})$, 18.9 $(C_{s}H_{3Ala})$, 18.4 $(C_{s}H_{3Val})$ ppm. **IR** (film) v 3339

(NH broad), 2965, 2930, 2871 (C-H), 1633 (C=O urea), 1249, 770 cm⁻¹. $[\alpha]_D^{20} = +3.6$ (c =

Residue	NH	N'H	α	β	γ	δ	3	CH ₂	СН	Δδ
Aze								4.21		
Aib ₃	7.25	/	3.41 / 3.36		/					0.05
Aib ₂	6.03	/	3.42 / 3.29		/					0.13
Aib ₁	6.18	/	3.63 / 3.21		/					0.42
Val	6.25	6.19	3.54 / 2.43	3.70	1.59	0.92 / 0.91				1.11
Ala	6.38	5.83	3.56 / 2.34	3.92	1.03					1.22
Leu	5.93	5.49	3.44 / 2.43	4.00	1.20	1.67	0.88 / 0.86			1.01
<i>i</i> Pr	5.69							1.12	3.79	

1.00; TFE). **HRMS** (ESI⁺): m/z calcd for C₅₀H₈₅O₇N₁₄ [M+H]⁺ 993.6720, found 993.6714.

NMR spectra of synthesized peptides





¹H NMR spectrum of **AzeAib4-(L)-PheNH***t***Bu** (400 MHz, CDCl₃):



¹³C NMR spectrum of AzeAib₄-(L)-*t*LeuNH*t*Bu (100 MHz, CDCl₃/CD₃OH 97:3):





¹³C NMR spectrum of AzeAib₄-(D)-AlaOtBu (100 MHz, CDCl₃):





¹H NMR spectrum of AzeAib₄-(L)-ValOtBu (400 MHz, CDCl₃):

¹³C NMR spectrum of AzeAib₄-(L)-ValOtBu (100 MHz, CDCl₃):





¹³C NMR spectrum of AzeAib₄-(L)-PheOtBu (125 MHz, CDCl₃):





¹³C NMR spectrum of AzeAib₈-(L)-AlaOtBu (100 MHz, CDCl₃):



¹H NMR spectrum of **AzeAib₁₁AlaOtBu** (400 MHz, CDCl₃):



¹³C NMR spectrum of AzeAib₁₁AlaOtBu (100 MHz, CDCl₃):



¹H NMR spectrum of AzeAib₁₂AlaOtBu (400 MHz, CDCl₃) :



¹H NMR spectrum of N₃Aib₄-(L)-AlaNH*t*Bu (500 MHz, CDCl₃):



¹³C NMR spectrum of N₃Aib₄-(L)-AlaNH*t*Bu (125 MHz, CDCl₃):





¹H NMR spectrum of N₃Aib₄-(L)-PheNH*t*Bu (500 MHz, CDCl₃):

f1 (ppm) - 2E+07 - 1E+07 - 0 - -1E+07



¹³C NMR spectrum of N₃Aib₄-(L)-*t*LeuNH*t*Bu (100 MHz, CDCl₃):





¹³C NMR spectrum of N₃Aib₄-(L)-AlaOtBu (100 MHz, CDCl₃):





¹³C NMR spectrum of N₃Aib₄-(L)-ValOtBu (100 MHz, CDCl₃):



¹H NMR spectrum of N₃Aib₄-(L)-ValOtBu (400 MHz, CDCl₃):



 ^{13}C NMR spectrum of $N_3\text{Aib}_4\text{-}(\text{L})\text{-PheO}t\text{Bu}$ (125 MHz, CDCl₃) :





¹³C NMR spectrum of N₃Aib₈-(L)-AlaOtBu (100 MHz, CDCl₃):





¹H NMR spectrum of N₃Aib₁₂-(L)-AlaOtBu (400 MHz, CDCl₃):



¹H NMR spectrum of **Aze-Aib^u-Aib^u-Val^u-Ala^u-Leu^u-NH***i***Pr (500 MHz, CD₃OH) :**





COSY spectrum of Aze-Aib^u-Aib^u-Val^u-Ala^u-Leu^u-NH*i*Pr (500 MHz, CD₃OH):



HSQC spectrum of Aze-Aib^u-Aib^u-Val^u-Ala^u-Leu^u-NH*i*Pr (CD₃OH):













HSQC spectrum of Aze-Aib^u-Aib^u-Aib^u-Val^u-Ala^u-Leu^u-NH*i*Pr (CD₃OH):

¹H NMR spectrum of **AzeCl** (500 MHz, CDCl₃):



Determination of the helical excess

The oligomers **8a-d** and **8f-g** (**Figure S1**) capped with an enantiomerically enriched ¹³C-monolabelled probe were previously used as model compounds to determine by NMR the effect of a chiral amino acid introduced at the C-terminus on the screw sense preference of the Aib helix in methanol.^[1]



Figure S1: Peptides 8a-j.

In this method, the local helical excess (h.e.), which quantifies the excess of the major helix (M or P) at the probe, is determined for each chiral amino acid using the following formula:

h.e. = ([P]-[M])/([P]+[M]) =
$$\Delta \delta_{\text{fast}} / \Delta \delta_{\text{slow}}$$

where $\Delta \delta_{slow}$ and $\Delta \delta_{fast}$ are the ¹³C labelled probe anisochronicity at slow and fast exchange regime of the helix, respectively measured at -70 °C and 20 °C.

Furthermore the relative intensity of the ${}^{13}C$ signals of the enantioselectivity isotopically enriched probe provides the absolute screw sense of the helix (*M* or *P*).

The helical excess as well as the absolute screw sense previously reported in methanol^[1] are given **Table S1** (Entries 1-7). A similar approach using the oligomers **8a-d** and **8f-g** was employed to determine the helical excess and the absolute screw in THF and the results are given **Figure S2**, **Figure S3** and **Table S1** (entries 1-7).

The local helical excesses of longer peptides (n =8, 11 and 12; **Figure S1**) were estimated assuming an exponential decay of the helical excess with the number n of Aib residues.^[5] The helical excess h.e.(n) were calculated by extrapolation of the helical excess of tetramer **8d** (n = 4) using the following formula:

h.e.(n) =
$$(1-f)^{n-4} \times h.e.(4)$$

where f is the per-residue decrease in h.e.

f = 7.7% in MeOH and f = 1.3% in THF. The results of the calculations for n =8, 11 and 12 are furnished **Table S1** (Entries 8-10).



Figure S2: DEPT-135 spectra of peptides **8b-d** and **8f-g** in THF-8d, showing the anisochronicity $\Delta\delta$ of the ¹³C-labelled probe.



Figure S2: Variation of the ¹³C-labelled probe anisochronicity $\Delta\delta$ measured in THF-8d with the temperature in the case of peptide **8a**.

Table S1: Local helical excess and absolute screw sense of helix determined in MeOH and in THF.

						MeOH		THF	
Entry	peptide	\mathbf{R}^1	R ²	Y	n	h.e. (%)	$\Delta \delta_{\rm fast}$ (ppb)	$\Delta \delta_{slow}$ (ppb)	h.e. (%)
1	8 a	Me	Η	NH <i>t</i> Bu	4	75 (P)	2434	2557 ^a	95 (P)
2	8b	CH ₂ Ph	Н	NH <i>t</i> Bu	4	70 (P)	2308	/	90 (P)
3	8c	<i>t</i> Bu	Н	NH <i>t</i> Bu	4	65 (P)	2510	/	98 (P)
4	8d	Me	Н	OtBu	4	55 (M)	1413	/	55 (M)
5	8 e	Н	Me	OtBu	4	55 (P)	/	/	55 (P)
6	8 f	iPr	Н	OtBu	4	46 (M)	1332	/	52 (M)
7	8g	CH ₂ Ph	Н	OtBu	4	34 (M)	902	/	35 (M)
8	8h	Me	Н	OtBu	8	40 (M)	/	/	52 (M)
9	8 i	Me	Η	OtBu	11	31 (M)	/	/	50 (M)
10	8j	Me	Н	OtBu	12	29 (M)	/	/	49 (M)

^a $\Delta \delta_{slow}$ determined at low temperature (-70 °C) and used as a constant value for the calculation of the helical excess whatever

the chiral amino acid considered.

NMR and CD analysis of peptides 2a-j and 2x

Table S2: Anisochronicity $\Delta\delta$ of the methylene groups of the dibenzazepine probe and molar ellipticity $\theta_{250 \text{ nm}}$ measured in MeOH for peptides **2a-j** and **2x**.

Fntry	Pentide	\mathbf{R}^1	\mathbf{R}^1 \mathbf{R}^2		n	Δδ	θ at 250 nm
Liiti y	repute	К	Ν	1	п	(ppm)	$(\text{deg.cm}^2 \text{dm}^1)$
1	2a	Me	Н	NH <i>t</i> Bu	4	369	32400
2	2b	CH ₂ Ph	Н	NH <i>t</i> Bu	4	323	27300
3	2c	<i>t</i> Bu	Н	NH <i>t</i> Bu	4	326	28300
4	2e	Н	Me	OtBu	4	264	23500
5	2d	Me	Н	OtBu	4	264	-24500
6	2f	iPr	Н	OtBu	4	229	-19400
7	2g	CH ₂ Ph	Н	OtBu	4	182	-16200
8	2h	Me	Н	OtBu	8	195	-17200
9	2i	Me	Н	OtBu	11	/	/
10	2j	Me	Н	OtBu	12	139	-12800
11	$2\mathbf{x}$	/	/	OtBu	4	0	300

^a Data not available due to the low solubility of peptide **2i** in MeOH.



Figure S4: Portion of the ¹H NMR in THF-8d of **2a-d** and **2f-j**, showing the anisochronicity $\Delta\delta$ of the methylene proton of the dibenzazepine probe.

Table S3: Anisochronicity $\Delta \delta$ of the methylene groups of the dibenzazepine probe measured in THF for peptides **2a-d** and **2f-j**.

Entry	Peptide	R^1	R ²	Y	n	Δδ
5	1					(ppm)
1	2a	Me	Η	NH <i>t</i> Bu	4	491
2	2b	CH ₂ Ph	Η	NH <i>t</i> Bu	4	451
3	2c	<i>t</i> Bu	Η	NH <i>t</i> Bu	4	495
4	2d	Me	Н	OtBu	4	291
5	2f	iPr	Н	OtBu	4	279
6	2g	CH ₂ Ph	Н	OtBu	4	206
7	2h	Me	Н	OtBu	8	270
8	2i	Me	Η	OtBu	11	264
9	2j	Me	Η	OtBu	12	261



Figure S2: CD spectra obtained by mixing peptides 2d and 2e in various proportions in methanol.

Table S3: Anisochronicity $\Delta\delta$ of the methylene groups of the dibenzazepine probe and molar ellipticity $\theta_{250 \text{ nm}}$ measured in MeOH when peptides **2d** and **2e** are mixed in various proportions.

2e/2d	Δδ	θ at 250 nm
	(ppm)	$(degcm^2 dm^{-1})$
100/0	264	23500
90/10	265	18900
80/20	265	13700
70/30	265	9100
60/40	265	4500
50/50	265	-100
40/60	/	-4400
30/70	/	-9500
20/80	265	-14100
10/90	/	-18700
0/100	264	-24500

References

- [1] B. A. F. Le Bailly, J. Clayden, *Chem. Commun.* **2014**, *50*, 7949–7952.
- [2] P. Scafato, G. Cunsolo, S. Labano and C. Rosini, *Tetrahedron* 2004, 60, 8801–8806.
- [3] J. Clayden, A. Castellanos, J. Solà, G. A. Morris, *Angew. Chem., Int. Ed.* 2009, 78, 32, 5962-5965.
- [4] R. Wechsel, J. Maury, J. Fremaux, S. P. France, G. Guichard, J. Clayden, *Chem. Commun.* 2014, *50*, 15006-15009.
- [5] B. A. F. Le Bailly, L. Byrne, V. Diemer, M. Foroozandeh, G. A. Morris and J. Clayden, *Chem. Sci.*, 2015, 6, 2313–2322.